Hyperfine (HYPR) Competitors $1.03 -0.04 (-3.74%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.07 +0.04 (+3.88%) As of 02/21/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HYPR vs. SMTI, AVR, RCEL, LUNG, ELMD, INGN, ZYXI, LAKE, DRTS, and OBIOShould you be buying Hyperfine stock or one of its competitors? The main competitors of Hyperfine include Sanara MedTech (SMTI), Anteris Technologies Global (AVR), AVITA Medical (RCEL), Pulmonx (LUNG), Electromed (ELMD), Inogen (INGN), Zynex (ZYXI), Lakeland Industries (LAKE), Alpha Tau Medical (DRTS), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. Hyperfine vs. Sanara MedTech Anteris Technologies Global AVITA Medical Pulmonx Electromed Inogen Zynex Lakeland Industries Alpha Tau Medical Orchestra BioMed Hyperfine (NASDAQ:HYPR) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Do analysts prefer HYPR or SMTI? Hyperfine presently has a consensus target price of $1.60, suggesting a potential upside of 55.34%. Sanara MedTech has a consensus target price of $47.00, suggesting a potential upside of 39.51%. Given Hyperfine's higher probable upside, research analysts clearly believe Hyperfine is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperfine 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sanara MedTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, HYPR or SMTI? Sanara MedTech has higher revenue and earnings than Hyperfine. Sanara MedTech is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHyperfine$11.03M6.81-$44.24M-$0.57-1.81Sanara MedTech$64.99M4.53-$4.30M-$0.99-34.03 Is HYPR or SMTI more profitable? Sanara MedTech has a net margin of -10.71% compared to Hyperfine's net margin of -309.42%. Sanara MedTech's return on equity of -19.86% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets Hyperfine-309.42% -57.54% -50.38% Sanara MedTech -10.71%-19.86%-10.91% Which has more risk and volatility, HYPR or SMTI? Hyperfine has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Does the media refer more to HYPR or SMTI? In the previous week, Hyperfine had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 1 mentions for Hyperfine and 0 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.00 beat Hyperfine's score of -1.00 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Overall Sentiment Hyperfine Negative Sanara MedTech Neutral Do institutionals & insiders have more ownership in HYPR or SMTI? 15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 29.4% of Hyperfine shares are owned by company insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer HYPR or SMTI? Sanara MedTech received 17 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 58.33% of users gave Sanara MedTech an outperform vote while only 44.44% of users gave Hyperfine an outperform vote. CompanyUnderperformOutperformHyperfineOutperform Votes444.44% Underperform Votes555.56% Sanara MedTechOutperform Votes2158.33% Underperform Votes1541.67% SummarySanara MedTech beats Hyperfine on 12 of the 18 factors compared between the two stocks. Get Hyperfine News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPR vs. The Competition Export to ExcelMetricHyperfineElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.14M$3.40B$5.77B$8.95BDividend YieldN/A1.65%4.78%3.85%P/E Ratio-1.8116.9626.4618.81Price / Sales6.8174.90449.1576.64Price / CashN/A45.9944.0437.47Price / Book0.883.867.634.64Net Income-$44.24M$92.00M$3.18B$245.69M7 Day Performance-14.17%4.33%-1.82%-2.63%1 Month Performance7.46%7.66%0.22%-2.37%1 Year Performance0.98%13.25%17.49%13.65% Hyperfine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPRHyperfine2.5051 of 5 stars$1.03-3.7%$1.60+55.3%+1.0%$75.14M$11.03M-1.81190Negative NewsSMTISanara MedTech2.1685 of 5 stars$35.02-0.7%$47.00+34.2%-10.3%$306.08M$64.99M-35.3760AVRAnteris Technologies GlobalN/A$7.99+1.9%$16.50+106.5%N/A$287.16MN/A0.00138RCELAVITA Medical1.5327 of 5 stars$10.57+20.4%$18.00+70.3%-44.0%$277.15M$50.14M-4.74130Upcoming EarningsAnalyst ForecastInsider TradeNews CoverageGap UpHigh Trading VolumeLUNGPulmonx2.7961 of 5 stars$6.97-5.6%$12.75+82.9%-38.2%$275.25M$68.68M-4.74250Earnings ReportNews CoverageELMDElectromed0.871 of 5 stars$31.89-4.0%N/A+85.4%$269.79M$54.72M44.29160Analyst DowngradeInsider TradeNews CoverageINGNInogen2.6796 of 5 stars$10.64-0.2%$7.00-34.2%+5.5%$253.45M$315.66M-4.731,030Upcoming EarningsZYXIZynex2.574 of 5 stars$7.54-0.4%$14.00+85.7%-43.5%$240.15M$184.32M50.271,100LAKELakeland Industries4.783 of 5 stars$24.03-1.9%$27.50+14.4%+45.1%$228.29M$124.69M-267.001,750DRTSAlpha Tau Medical2.9231 of 5 stars$3.14+2.6%$8.00+154.8%-12.1%$219.56MN/A-7.3080Positive NewsGap UpOBIOOrchestra BioMed2.738 of 5 stars$5.67+1.3%$16.25+186.6%-18.3%$215.52M$2.76M-3.524 Related Companies and Tools Related Companies Sanara MedTech Alternatives Anteris Technologies Global Alternatives AVITA Medical Alternatives Pulmonx Alternatives Electromed Alternatives Inogen Alternatives Zynex Alternatives Lakeland Industries Alternatives Alpha Tau Medical Alternatives Orchestra BioMed Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HYPR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperfine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperfine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
